skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

29 Total results for product and free and sample content found

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

AHA 2016: Type 2 diabetes treatment is shifting towards therapies with cardiovascular benefits

By Kevin Shannon 22 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

AHA 2016: Interim Data from ORION-1 Trial Encourage Further Development of Inclisiran

By Jack Allen 22 Nov 2016

Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

AHA 2016: EFFECT-HF supports use of iron deficiency as an independent therapeutic target in heart failure

By Kevin Shannon 22 Nov 2016

Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

AHA 2016: PIONEER-AF trial results will have minimal effect on Xarelto uptake

By Jack Allen 18 Nov 2016

Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

AHA 2016: Repatha causes atherosclerotic plaque regression, even at very low LDL-C levels

By Jack Allen 17 Nov 2016

The Phase III GLAGOV trial showed Repatha (evolocumab; Amgen/Astellas) treatment to reduce atherosclerotic plaque burden in an apparently dose-dependent manner, even at very small low-density lipoprotein-cholesterol (LDL-C) levels.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

AHA 2016: Significant increase in SGLT-2 inhibitor use expected in type 2 diabetes

By Kevin Shannon 15 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans expect recent CVOT data to lead to increased use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, despite uncertainty surrounding the mechanism of the drugs’ observed cardiovascular (CV) benefit.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

The US will continue to dictate the trends of the overall multiple sclerosis market

By Ines Guerra 09 Nov 2016

Generating over 80% of multiple sclerosis (MS) sales in 2025, the US will dictate the overall market dynamics during the entire forecast period.

Topics Research wire

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

Key late breaking and recommended sessions we will be investigating at AHA 2016

By Kevin Shannon 08 Nov 2016

Key late breaking and recommended sessions we will be investigating at AHA 2016

Topics Research wire Drug approval

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

Researchwire – Breast Cancer

By Nicola Leckenby 07 Nov 2016

There were an estimated 558,000 incident cases of breast cancer across the analyzed markets in 2015, with moderate growth foretasted over the next 20 years.

Topics Research wire Drug approval

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: